The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trastuzumab therapy in HER2-positive, metastatic breast cancer.
A. D. Smith
No relevant relationships to disclose
K. Guilbert
No relevant relationships to disclose
D. Lister
No relevant relationships to disclose
S. Streilein
No relevant relationships to disclose
V. C. Bourrier
No relevant relationships to disclose
B. Lozar
No relevant relationships to disclose
S. Navaratnam
No relevant relationships to disclose
G. A. Harding
No relevant relationships to disclose
M. W. Pitz
No relevant relationships to disclose